Apollomics Inc., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3 to April 24, 2024. The request, filed via EDGAR and dated April 22, 2024, follows the initial filing of the Registration Statement on April 1, 2024. The company seeks to have the Registration Statement, which pertains to the registration of securities for potential future offerings, declared effective at 5:00 p.m. Washington, D.C. time on the requested date or as soon as possible thereafter. Apollomics has designated Daniel Nussen of White & Case LLP as the contact person for any inquiries from the SEC and to receive notification upon the acceleration approval.

Apollomics Inc., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3 to April 24, 2024. The request, filed via EDGAR and dated April 22, 2024, follows the initial filing of the Registration Statement on April 1, 2024. The company seeks to have the Registration Statement, which pertains to the registration of securities for potential future offerings, declared effective at 5:00 p.m. Washington, D.C. time on the requested date or as soon as possible thereafter. Apollomics has designated Daniel Nussen of White & Case LLP as the contact person for any inquiries from the SEC and to receive notification upon the acceleration approval.